Zoetis Secures Health Canada Approval for Portela™ (relfovetmab Injection) to Relieve Osteoarthritis Pain in Cats Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain…
Advancing Transplant Innovation with First-of-Its-Kind Insights from Organ Donor-Derived Bone Marrow Ossium Health, a bioengineering company that developed a first-of-its-kind bank of bone marrow available on-demand, will present new clinical…
IDE034, a Bispecific Antibody-Drug Conjugate Licensed by Biocytogen to IDEAYA, Secures FDA IND Clearance Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq:…
Egypt Achieves Historic Milestone in Healthcare Sovereignty: Becomes Sixth Nation to Attain Plasma Self-Sufficiency with Grifols Partnership Plasma-derived medicines—a feat made possible through a groundbreaking five-year strategic alliance with Grifols,…
Bayer Launches Phase IIa Clinical Trial of Novel Therapy for Alport Syndrome Bayer has announced the initiation of a Phase IIa clinical trial evaluating BAY 3401016, an investigational monoclonal antibody…
Aetna Accelerates National Strategy to Simplify Healthcare for Providers and Patients Through Innovation, AI, and Integrated Care Models Aetna®, a CVS Health® company today announced significant progress on its ambitious,…
Bristol Myers Squibb’s Breyanzi Becomes First and Only CAR T Cell Therapy Approved by FDA for Relapsed or Refractory Marginal Zone Lymphoma Breyanzi® CD19-directed chimeric antigen receptor (CAR) T cell…
Merck Animal Health Secures FDA Conditional Approval for EXZOLT™ CATTLE-CA1—A Groundbreaking Tool Against New World Screwworm and Cattle Fever Tick Merck Animal Health, known globally as MSD Animal Health outside…
Cipla and Stempeutics Forge Landmark Partnership to Introduce India’s First Allogeneic Stem Cell Therapy for Knee Osteoarthritis Cipla Limited a global pharmaceutical leader with a legacy of patient-centric innovation—has officially…
Alnylam Pharmaceuticals Announces Strategic Refresh of Board of Directors to Propel Next Phase of Growth Alnylam Pharmaceuticals, Inc.the global pioneer and leader in RNA interference (RNAi) therapeutics, today announced a…
BioNTech Secures Overwhelming Shareholder Support, Meets Minimum Condition to Complete CureVac Exchange Offer BioNTech SE announced today that it has successfully met the minimum tender condition for its exchange offer…
Bristol Myers Squibb Advances ADEPT-2 Phase 3 Trial for Alzheimer’s-Related Psychosis Following Rigorous Data Review and FDA Alignment Bristol Myers Squibb has announced a significant update regarding its ADEPT-2 Phase…
